Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.840.31%
QQQ
720.060.15%
BTC/USD
78634.220.5767%
DIA
528.930.96%
GLD
402.071.16%
TLT
82.070.17%

Minerva Neurosciences Inc

NERVNASDAQ
Trade with Public
Trade with Public
$4.35
-0.0839-1.89%
Last update: Sep 8, 2:16 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Minerva Neurosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Minerva Neurosciences (NERV).

Price Target Range — 9 Quarters

Analyst Consensus — 3 Analysts

1S.Buy
1Buy
1Hold
Consensus RatingMarket Outperform# Analysts3Avg. Consensus PT$10Upside to Avg. PT+137.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026JefferiesBiren AminUpgradeHold→Buy$8→$10
Apr 15, 2026CitizensJason N. ButlerInitiateMarket Outperform$14
More with Benzinga EdgeGet Access

Analyst Ratings News

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.
Avi Kapoor

PRO
Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10

Jefferies analyst Biren Amin upgrades Minerva Neurosciences (NASDAQ:NERV) from Hold to Buy and raises the price target from $7.5 to $10.
Benzinga Newsdesk

PRO
Citizens Initiates Coverage On Minerva Neurosciences with Market Outperform Rating, Announces Price Target of $14

Citizens analyst Jason N. Butler initiates coverage on Minerva Neurosciences (NASDAQ:NERV) with a Market Outperform rating and announces Price Target of $14.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Raises Price Target to $7

HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and raises the price target from $4 to $7.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $4

HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and lowers the price target from $5 to $4.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $5 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Minerva Neurosciences (NASDAQ:NERV) with a Neutral and maintains $5 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved